Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Establishment Labs Holdings Q3 2026 Results: Net Loss of $10.7M, Loss Narrows

Establishment Labs Holdings Inc. reported 29,823,470 common shares outstanding as of November 5, 2026. The company's balance sheet shows a stable cash position of $75.8 million as of September 30, 2026, compared to $75.6 million at the end of 2025, while total current assets increased slightly to $255.7 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue72.053.8
Gross profit49.737.7
Profit before tax-10.1-10.7
Net income-10.7-11.1
EPS (diluted, $ a share)$-0.35$-0.38

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+33.9%
Gross margin69.1%
Operating margin-3.6%
Source

10-Q filed with the SEC, NASDAQ: ESTA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Establishment Labs Holdings Inc.: key numbers

Share price
$69.82Close, Nov 16
Market cap
$2.08B
Shares outstanding
29.82MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Establishment Labs Holdings Inc.

All →
8:26 AM ET 8-K
Financial Results

Establishment Labs Holdings Financial Results

Establishment Labs reported Q3 2026 revenue of $72.0 million, a 33.9% increase year-over-year, driven by 119% growth in the U.S. market. The company achieved its first-ever quarter of positive operating and free cash flow and raised its full-year 2026 revenue guidance to over $274 million.

Term
Q3 2026

“Third-quarter results reflect strong global revenue growth, increasing operating leverage and an important milestone in cash generation as we invest in innovation and commercial expansion.”

Peter Caldini, Chief Executive Officer

“We enter 2027 with a strong financial foundation and with significant opportunities and growth ahead of us, especially in minimally invasive and reconstruction. We expect fiscal 2027 to deliver growth of 25% and positive cash flow, setting the stage for many years to come.”

Peter Caldini, Chief Executive Officer
6:07 AM ET 8-K
Business Update

Establishment Labs Holdings Business Update

Establishment Labs Holdings Inc. entered into an amendment to its Master Supply Agreement with NuSil Technology LLC, extending the contract term from December 31, 2026, to December 31, 2031. The agreement secures the supply of medical-grade silicone for the company's products and includes updated terms for pricing, business continuity, and intellectual property.

Counterparty
NuSil Technology LLC
Term
5 years

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.